JP2018502860A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502860A5
JP2018502860A5 JP2017536526A JP2017536526A JP2018502860A5 JP 2018502860 A5 JP2018502860 A5 JP 2018502860A5 JP 2017536526 A JP2017536526 A JP 2017536526A JP 2017536526 A JP2017536526 A JP 2017536526A JP 2018502860 A5 JP2018502860 A5 JP 2018502860A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
amino acid
acid sequence
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017536526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502860A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/012650 external-priority patent/WO2016112292A1/en
Publication of JP2018502860A publication Critical patent/JP2018502860A/ja
Publication of JP2018502860A5 publication Critical patent/JP2018502860A5/ja
Pending legal-status Critical Current

Links

JP2017536526A 2015-01-08 2016-01-08 Mk2阻害ペプチド製剤 Pending JP2018502860A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101190P 2015-01-08 2015-01-08
US62/101,190 2015-01-08
PCT/US2016/012650 WO2016112292A1 (en) 2015-01-08 2016-01-08 Formulation of mk2 inhibitor peptides

Publications (2)

Publication Number Publication Date
JP2018502860A JP2018502860A (ja) 2018-02-01
JP2018502860A5 true JP2018502860A5 (https=) 2019-02-14

Family

ID=56356475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017536526A Pending JP2018502860A (ja) 2015-01-08 2016-01-08 Mk2阻害ペプチド製剤

Country Status (14)

Country Link
US (2) US10087225B2 (https=)
EP (1) EP3242886A4 (https=)
JP (1) JP2018502860A (https=)
KR (1) KR20170102900A (https=)
CN (1) CN107406489A (https=)
AU (1) AU2016205125A1 (https=)
BR (1) BR112017014737A2 (https=)
CA (1) CA2972916A1 (https=)
HK (1) HK1246807A1 (https=)
MX (1) MX2017008994A (https=)
RU (1) RU2017128077A (https=)
SG (1) SG11201705559RA (https=)
WO (1) WO2016112292A1 (https=)
ZA (1) ZA201704495B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2019176618A1 (ja) 2018-03-13 2019-09-19 株式会社Adeka 非水電解質二次電池
US20210322310A1 (en) * 2020-04-16 2021-10-21 Cai Gu Huang Inhalable Formulation of a Solution Containing Tiotropium Bromide
CN111647088B (zh) * 2020-06-29 2023-05-02 东北师范大学 细胞渗透短肽tat-hns-3及对炎性疾病的应用
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
DE3682457D1 (de) 1985-07-30 1991-12-19 Glaxo Group Ltd Geraet zur verabreichung von medikamenten an patienten.
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US20080176790A1 (en) * 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
DK2617431T3 (en) 2007-01-10 2017-07-10 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and applications therefor
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
CN102256613B (zh) * 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
EP2378875B1 (en) * 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
KR101862291B1 (ko) * 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법
US20140072613A1 (en) 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
US9102015B2 (en) * 2013-03-14 2015-08-11 Siemens Energy, Inc Method and apparatus for fabrication and repair of thermal barriers
WO2014169256A2 (en) * 2013-04-11 2014-10-16 Vanderbilt University Polyplexes

Similar Documents

Publication Publication Date Title
JP2018502860A5 (https=)
Jiang et al. Bioinspired design of mannose-decorated globular lysine dendrimers promotes diabetic wound healing by orchestrating appropriate macrophage polarization
ES2476842T3 (es) Inhibidores polipept�dicos de HSP27 quinasa y usos de los mismos
AU2020280993B2 (en) Compositions and methods of using islet neogenesis peptides and analogs thereof
RU2743431C2 (ru) Липосомы, содержащие проникающие в клетки пептиды и тетраэфирные липиды, для пероральной доставки макромолекул
JP2014533235A5 (https=)
US20240051997A1 (en) Sap and peptidomimetic compositions for reducing symptoms of inflammation
CN106456707B (zh) 干粉肽药剂
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
JP2020518287A5 (https=)
WO2010060497A1 (en) A nonapeptide with anti-tumour activity
JP7751641B2 (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物
RU2017128077A (ru) Составы, содержащие пептиды, ингибирующие мк2
US11571455B2 (en) Methods and compositions for treating alcoholic liver disease
JP2023547405A (ja) Cas9-RNP及び他の核タンパク質カーゴの形質導入のために適合された最小長のシャトル剤ペプチド及びそのバリアント
KR20230121823A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
CN119285744A (zh) 逆向-反转肽
CN105012936A (zh) 抗菌肽bf-30在制备治疗或预防血栓性疾病药物中的应用
CN105079780B (zh) 一种特异结合trb3的多肽在治疗腹主动脉瘤中的应用
US7425217B2 (en) System and method for inhibiting cellular proliferation with tachykinins
US8357653B2 (en) System and method for inhibiting cellular proliferation with tachykinins
EA038363B1 (ru) Водный аэрозоль для ингаляции, не содержащий добавок и/или стабилизаторов, содержащий циклический пептид формулы x1-gqretpegaeakpwy-x2
WO2021243148A2 (en) Methods and compositions for treating alcoholic liver disease
US20230391841A1 (en) Macrocyclic peptides
Siekmeier et al. Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome